Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.60 |
| ▸ | CNR1 | P21554 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118376 | 0.95 | MCHR1 (0.66) | MCHR1CNR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4118978 | 0.91 | GAA (0.59) | MCHR1CNR1MEN1KMT2AGAA | |
| SCHEMBL4115328 | 0.91 | MCHR1 (0.61) | MCHR1CNR1MEN1KMT2AGAA | |
| SCHEMBL4107405 | 0.90 | MCHR1 (0.60) | MCHR1CNR1MEN1KMT2AGAA | |
| SCHEMBL4117727 | 0.89 | CNR1 (0.60) | MCHR1CNR1MEN1KMT2AGAA | |
| SCHEMBL4107391 | 0.88 | MCHR1 (0.64) | MCHR1CNR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4107568 | 0.88 | MCHR1 (0.58) | MCHR1MEN1KMT2A | |
| SCHEMBL4116381 | 0.87 | MCHR1 (0.58) | MCHR1CNR1MEN1KMT2AGAA | |
| SCHEMBL4112236 | 0.87 | CNR1 (0.56) | MCHR1CNR1MEN1KMT2AGAA | |
| SCHEMBL4106129 | 0.85 | CNR1 (0.57) | MCHR1CNR1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | claimed |
| EP-1711175-A1 | DIUREA DERIVATIVES | Active Biotech AB (SE) | 2006-10-18 | — | — | EP | claimed |
| WO-2005074919-A1 | DIUREA DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1711175-A1 | DIUREA DERIVATIVES | Active Biotech AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005074919-A1 | DIUREA DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | IL2, CASP2, MAVS | MCHR1 4128/4885CNR1 3201/4885MEN1 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.